Vol. 19/No. 10

The BOSTON trial is randomizing patients with relapsed/refractory multiple myeloma to a triplet combination of selinexor (KPT-330), bortezomib (Velcade), and dexamethasone versus a combination of bortezomib and dexamethasone.

A. Keith Stewart, MB, ChB, and a panel of hematology experts review data concerning emerging frontline strategies for multiple myeloma that were presented at the 2017 ASH Annual Meeting.

There is very little evidence of clinical validity or clinical utility to justify the widespread use of circulating tumor DNA assays in most patients with advanced cancer, according to a panel of experts from ASCO and the College of American Pathologists

Investigators from Montefiore developed a novel combination that has now demonstrated early-stage efficacy in metastatic lung cancer.

The National Comprehensive Cancer Network has developed its first set of recommendations to help clinicians manage toxicities in the recognition of the variety of immune-related adverse events that patients receiving checkpoint blockade immunotherapy may experience.

The National Comprehensive Cancer Network has overhauled its guidelines for managing prostate cancer with a greater emphasis on risk stratification for molecular testing and therapy choices.

The unique biological characteristics of uveal melanoma have prompted the National Comprehensive Cancer Network to develop the first set of guidelines for the diagnosis and management of the rare cancer.

Specific guidance in the HIV-infected population was not previously available, partly because persons living with HIV were previously excluded from cancer clinical trials, creating a knowledge gap.

More than a third of the new indications for oncology drugs that became available for patient care during the past 25 years entered clinical practice as a result of the FDA’s accelerated approval program.

Experts across the medical spectrum weigh in on requesting prior authorization, and how that process effects the treatment of cancer.

The NCCN guideline committee has designated a direct oral anticoagulant as a preferred frontline treatment for most patients with cancer-associated venous thromboembolism.

Maurie Markman, MD, discusses the cause and impact of the opioid addiction epidemic in the United States.